We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Myriad Genetics Inc
4 own
6 watching
Current Price
$0
$0.07
(0.28%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,888.71M
52-Week High
28.18
52-Week Low
13.92
Average Volume
0.01M
Dividend Yield
--
P/E Ratio
22.73
Market Capitalization1,888.71M52-Week High28.1852-Week Low13.92Average Volume0.01MDividend Yield--P/E Ratio22.73What does the Myriad Genetics Inc do?
Myriad Genetics, Inc., a personalized medicine company, focuses on the development and marketing of predictive, personalized, and prognostic medicine tests worldwide. It operates through two segments, Diagnostics and Other. The Diagnostics segment primarily provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease; identify a patient's likelihood of responding to drug therapy; guide a patient's dosing to ensure optimal treatment; and assess a patient's risk of disease progression and disease recurrence. The Other segment provides testing products and services to the pharmaceutical, biotechnology, and medical research industries; and research and development, and clinical services for patients. Its molecular diagnostic DNA sequencing tests include myRisk Hereditary cancer, a test for hereditary cancers; BRACAnalysis and BART, which are tests for hereditary breast and ovarian cancers; BRACAnalysis CDx test for use in identifying ovarian cancer patients with suspected deleterious germline; and Tumor BRACAnalysis CDx test that is used to predict DNA damaging agents, such as platinum based chemotherapy agents and poly ADP ribose inhibitors. The company also provides COLARIS test for colorectal and uterine cancers; COLARIS AP test for colorectal cancer; Vectra DA protein detection test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for prostate cancer; EndoPredict RNA expression test for breast cancer; myPath Melanoma RNA expression test for diagnosing melanoma; myChoice homologous recombination deficiency (HRD) test to measure three modes of HRD; and myPlan lung cancer, an RNA expression test for lung cancer. Myriad Genetics, Inc. has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Read More
How much money does Myriad Genetics Inc make?
News & Events about Myriad Genetics Inc.
Globe Newswire
1month ago
New program will increase access to affordable genetic testing while also helping to identify and elevate high-risk patient careSALT LAKE CITY, April 12, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and SimonMed Imaging, one of ...
Ticker Report
2 months ago
Myriad Genetics, Inc. (NASDAQ:MYGN Get Rating) COO Nicole Lambert sold 6,433 shares of the companys stock in a transaction dated Monday, March 27th. The shares were sold at an average price of $23.48, for a total transaction of $151,046.84. Following the completion of the transaction...
Zolmax
2 months ago
Myriad Genetics, Inc. (NASDAQ:MYGN Get Rating) COO Nicole Lambert sold 6,433 shares of the companys stock in a transaction dated Monday, March 27th. The shares were sold at an average price of $23.48, for a total transaction of $151,046.84. Following the completion of the transaction...
Globe Newswire
3 months ago
Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industrySALT LAKE CITY, March 02, 2023 (GLOBE NEWSWIRE) -- Myriad Genetic, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, and Illumina Inc. (...
Globe Newswire
3 months ago
SALT LAKE CITY, March 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced its support for the first evidence-based expanded carrier screening (ECS) practice guidelines for reproductive risk assessment published by ...
Frequently Asked Questions
Frequently Asked Questions
What is Myriad Genetics Inc share price today?
Can Indians buy Myriad Genetics Inc shares?
How can I buy Myriad Genetics Inc shares from India?
Can Fractional shares of Myriad Genetics Inc be purchased?
What are the documents required to start investing in Myriad Genetics Inc stocks?
What is today’s traded volume of Myriad Genetics Inc?
What is today’s market capitalisation of Myriad Genetics Inc?
What is the 52-Week High and Low Range of Myriad Genetics Inc?
What percentage is Myriad Genetics Inc down from its 52-Week High?
What percentage is Myriad Genetics Inc up from its 52-Week Low?
Current Price
$0
$0.07
(0.28%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.